Invention Grant
- Patent Title: Universal chimeric antigen receptor T cells specific for CD22
-
Application No.: US16498276Application Date: 2018-03-30
-
Publication No.: US11690873B2Publication Date: 2023-07-04
- Inventor: Cecile Schiffer-Mannioui , Philippe Duchateau , Anne-Sophie Gautron
- Applicant: CELLECTIS SA
- Applicant Address: FR Paris
- Assignee: CELLECTIS SA
- Current Assignee: CELLECTIS SA
- Current Assignee Address: FR Paris
- Agency: Casimir Jones, S.C.
- Agent Peter J. Schlueter
- Priority: DK 201770239 2017.03.31 DK 201770240 2017.03.31 DK 201770542 2017.06.30 WO TEP2017076800 2017.10.19
- International Application: PCT/EP2018/058368 2018.03.30
- International Announcement: WO2018/178378A 2018.10.04
- Date entered country: 2019-09-26
- Main IPC: C07K14/705
- IPC: C07K14/705 ; C07K19/00 ; A61P35/00 ; A61K39/395 ; A61K35/17 ; C07K14/725 ; C07K16/28 ; A61P35/02 ; A61K31/365
Abstract:
The present invention relates to new CD22 Chimeric Antigen Receptors (CD22 CAR), an engineered immune cell endowed with said new CD22 CAR and comprising at least inactivated TRAC gene for use in therapy. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.
Public/Granted literature
- US20210100839A1 NEW UNIVERSAL CHIMERIC ANTIGEN RECEPTOR T CELLS SPECIFIC FOR CD22 Public/Granted day:2021-04-08
Information query
